Enanta Pharmaceuticals Inc (ENTA)

[stockbettor]

Real life treatment experience with Sovaldi.

http://www.medpagetoday.com/MeetingCoverage/AASLD/48495

Meanwhile, Dieterich said, much the same results came out of analysis of 955 patients whose data was obtained from electronic records in the TRIO network of pharmacies.
His analysis included 822 patients intended to be treated for 12 weeks with the same regimens as the HCV-Target cohort, which had some longer treatment periods.
Among the 822, Dieterich said, the overall SVR12 was 79%, but the group included 79 people who dropped out. The SVR12 among those who completed treatment -- the per-protocol cohort of 743 patients -- was 88%.
The rates are "remarkably high, considering the real-life heterogeneous population here," Dieterich said.
Broken down by genotype and regimen, the intent-to-treat SVR12s were: For sofosbuvir, interferon, and ribavirin 72% in genotype 1 and 67% in genotypes 4, 5, and 6 combined; for sofosbuvir plus ribavirin 50% for genotype 1 and 84% for genotype 2, and for sofosbuvir and simeprevir, plus or minus ribavirin 82% for genotype 1.
The most important predictor of response was cirrhosis, Dieterich said.